Apimeds Pharmaceuticals US (APUS) Total Non-Current Liabilities (2023 - 2025)
Apimeds Pharmaceuticals US's (APUS) quarterly Total Non-Current Liabilities came in at $9.2 million in Q4 2025, up 1352.75% on a QoQ basis from $634589.0 in Q2 2025.
Apimeds Pharmaceuticals US (APUS) Total Non-Current Liabilities (2023 - 2025) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has 2 years of Total Non-Current Liabilities data on file, last reported at $9.2 million in Q4 2025.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $9.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.2 million (changed N/A YoY) and the FY2025 annual result came in at $9.2 million, changed N/A from the prior year.
- Total Non-Current Liabilities rose to $9.2 million in Q4 2025, from $634589.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $9.2 million in Q4 2025 to a low of $321329.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Apimeds Pharmaceuticals US | 8.00 Mn | 8.00 Mn | - | 19.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.22 Mn |
| Jun 30, 2025 | 634,589.00 |
| Dec 31, 2023 | 321,329.00 |